PD-1-targeted therapeutic strategies for advanced or recurrent gastric and gastroesophageal junction cancer: a systematic review and network meta-analysis

The optimal strategy for integrating programmed cell death protein 1 (PD-1) blockade into treatment frameworks for patients with unresectable or recurrent advanced gastric and gastroesophageal junction cancers remains unclear. This network meta-analysis compared the therapeutic effectiveness and safety profiles of diverse PD-1-based approaches in this population.